SALT LAKE CITY--(BUSINESS WIRE)--BioUtah, Utah’s only trade association dedicated solely to the life sciences, in partnership with the University of Utah’s Center for Technology & Venture Commercialization (TVC), today announced the opening of the 2020 Entrepreneur & Investor Life Science Summit (E&I Summit) on February 28, at the University of Utah’s Cleone Peterson Eccles Alumni House. For a complete Summit agenda and speaker list visit www.eilifesciencessummit.org.
The E&I Summit, sponsored by Simpson Thacher, is especially designed to showcase Utah's burgeoning life sciences sector and provide important insights for early stage companies from experts in various fields. There is no better way for startups and emerging growth companies to gain broad exposure to some of the best life sciences corporations, venture capital firms, and angel investors in the business.
The full day conference will feature keynote speakers, David Bearss, PhD, founder and CEO of Tolero Pharmaceuticals, and Monica DiCenso, managing director and Head of Global Investment Opportunities Group, with J.P. Morgan Private Bank. An impressive array of local and national investors will be participating in the Summit.
Nine promising Utah startup companies will pitch their concepts and products to Summit investors and guests. The National Institute of Health’s (NIH) Lili Portilla, who oversees the NIH's National Center for Advancing Translational Sciences’ (NCATS) technology transfer functions, as well as NCATS’ Small Business Innovation Research grants, will be meeting with companies during the course of the Summit. Angel MD, a crowd sourcing company with an extensive investor network of medical professionals, will also personally meet with companies.
“The E&I Summit is fast-becoming the go-to conference for Utah’s life sciences innovators and entrepreneurs. It’s an annual forum where emerging companies and investors can come together,” said Kelvyn Cullimore, president and CEO of BioUtah.
“We’re excited to kick-off this year’s E&I Summit on the 28th and share our growing life sciences ecosystem with the investor community,” said Keith Marmer, associate vice president and executive director of the TVC.
“Utah is already a hub for life sciences innovation,” said Brandi Simpson, CEO of Navigen Pharmaceuticals and chair of the BioUtah Board of Directors. “We want to build on that and help deliver the next generation of medical breakthroughs to patients suffering with serious illness."
About BioUtah
BioUtah is an independent 501(c)(6) trade association serving Utah’s life sciences industry. Its member companies reflect a broad spectrum of the industry with strengths in medical device manufacturing and services, research and testing, biotechnology, biopharmaceuticals, and advanced diagnostics, amongst others; and are a key driver of Utah’s economy.
About the Center for Technology & Venture Commercialization
The Center for Technology & Venture Commercialization is dedicated to helping the University of Utah’s faculty inventors bring their innovations to market. TVC is responsible for all aspects of invention management, patent prosecution, licensing, startup formation and support, equity management and early-stage funding. The center’s mission is to expand the university’s reputation for innovation, and positively impact society. TVC is proud to help foster this spirit of discovery.
